Amylyx completes subject enrollment in ALS therapy trial

Amylyx Pharmaceuticals has completed participant enrolment in the Phase III PHOENIX clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) in amyotrophic lateral sclerosis (ALS) patients.